A Phase 2 interventional study of Placebo matching with BMS-945429 and Placebo matching with BMS-945429 in Crohn's Disease, sponsored by CSL Behring. Terminated at 56 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-03.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 242nd largest by enrollment of the 528 interventional ones that give a count, is one of 25 that started in 2012, is one of 141 in phase 2, and was the 203rd registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 25 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Placebo matching with BMS-945429
Biological: Placebo matching with BMS-945429 · Biological: BMS-945429
Biological: Placebo matching with BMS-945429 · Biological: BMS-945429
Biological: Placebo matching with BMS-945429 · Biological: BMS-945429
Biological: Placebo matching with BMS-945429 · Biological: BMS-945429
Biological: Placebo matching with BMS-945429
Biological: BMS-945429
Biological: BMS-945429
Biological: BMS-945429
Injection, Intravenous (IV), 0 mg, Day One Only, One Day
Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
Injection, Intravenous (IV), 600 mg, Day One Only, One Day
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
Also known as: Clazakizumab
Injection, Intravenous (IV), 300 mg, Day One Only, One Day
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
Also known as: Clazakizumab
Injection, Intravenous (IV), 150 mg, Day One Only, One Day
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
Also known as: Clazakizumab
Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
Also known as: Clazakizumab
Percent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI)
CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity
Time frame: At 8 weeks during the Induction Period
Percent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI
CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity
Time frame: At 8 weeks during the Induction Period
Change From Baseline at Week 8 and 12 of Inflammatory Bowel Disease Questionnaire (IBDQ) Score
IBDQ consists of 32 questions divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.
Time frame: Week 8 and Week 12
Number of Participants During the Induction Period With Anti-clazakizumab Antibodies
Time frame: Up to Week 12
Steady-state Trough Concentration (Cmin) of Clazakizumab During the Induction Period
Time frame: Week 4, Week 8
Observed Maximum Concentration (Cmax) of Clazakizumab During the Induction Period
Time frame: Week 0 and Week 4
Area Under the Plasma Concentration-time Curve in One Dosing Interval [AUC(TAU)] of Clazakizumab During the Induction Period
Time frame: Week 0, Week 4, Week 8
| Milestone | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Started | 18 | 9 | 9 | 18 | 18 |
| Completed | 11 | 4 | 4 | 6 | 9 |
| Not completed | 7 | 5 | 5 | 12 | 9 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Adverse event | 1 | 1 | 2 | 2 | 0 |
| Withdrew: Discontinued study treatment | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 | 1 |
| Withdrew: Participant no longer meets study criteria | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Administrative reason by sponsor | 4 | 2 | 3 | 5 | 5 |
CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity
| percentage of participants | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Percent of Participants With Clinical Remission (CDAI<150) as Measured by the Crohn's Disease Activity Index (CDAI) | 17.6 | 33.3 | 0 | 18.8 | 12.5 |
CDAI scores range from 0 to 600. A score of less than 150 corresponds to relative disease quiescence (remission); 150 to 219, mildly active disease; 220 to 450, moderately active disease; and greater than 450, severe disease. A decrease in greater than 100 points indicates a clinically significant improvement in disease activity
| percentage of participants | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Percent of Participants With Clinical Response (>100 Point Decrease in CDAI) During Induction Period as Measured by CDAI | 29.4 | 33.3 | 25.0 | 31.3 | 12.5 |
IBDQ consists of 32 questions divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.
| score on a scale | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Week 8 | 11.8 ± 23.01 | -2.0 ± 28.93 | 1.9 ± 36.46 | 15.5 ± 32.01 | 14.8 ± 33.7 |
| Week 12 | 10.0 ± 33.65 | 21.8 ± 34.62 | 1.4 ± 61.06 | 20.1 ± 36.32 | 18.7 ± 35.62 |
| participants | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Number of Participants During the Induction Period With Anti-clazakizumab Antibodies | 0 | 0 | 0 | 0 | 1 |
| ug/mL | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|
| Week 4 | — | — | 21.0816 ± 8.19326 | — |
| Week 8 | — | — | 36.1026 ± 14.49349 | — |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Up to 12 weeks per participant. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 2/18 (11.1%) | 1/18 (5.6%) |
| Clazakizumab (150 IV/100 SC) | 0/9 (0%) | 2/9 (22.2%) | 2/9 (22.2%) |
| Clazakizumab (300 IV/100 SC) | 1/9 (11.1%) | 2/9 (22.2%) | 3/9 (33.3%) |
| Clazakizumab (400 SC/200 SC) | 0/18 (0%) | 6/18 (33.3%) | 8/18 (44.4%) |
| Clazakizumab (600 IV/200 SC) | 0/18 (0%) | 4/18 (22.2%) | 2/18 (11.1%) |
| Event | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Cronh's diseaseGastrointestinal disorders | 0/18 | 1/9 | 0/9 | 2/18 | 3/18 |
| Intestinal perforationGastrointestinal disorders | 0/18 | 0/9 | 1/9 | 0/18 | 1/18 |
| Large intestine perforationGastrointestinal disorders | 0/18 | 1/9 | 0/9 | 0/18 | 0/18 |
| PeritonitisInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 1/18 |
| ErysipelasInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| Pelvic abscessInfections and infestations | 0/18 | 1/9 | 0/9 | 0/18 | 0/18 |
| Septic shockInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| PericarditisCardiac disorders | 0/18 | 1/9 | 0/9 | 0/18 | 0/18 |
| Anal fistulaGastrointestinal disorders | 1/18 | 0/9 | 0/9 | 1/18 | 0/18 |
| Anorectal disorderGastrointestinal disorders | 0/18 | 0/9 | 0/9 | 1/18 | 0/18 |
| Event | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/18 | 0/9 | 0/9 | 2/18 | 1/18 |
| Injection site reactionGeneral disorders | 0/18 | 0/9 | 0/9 | 2/18 | 0/18 |
| Chest painGeneral disorders | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| ErysipelasInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| PeritonitisInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| Septic shockInfections and infestations | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| Vulvovaginal candidiasisInfections and infestations | 0/18 | 1/9 | 0/9 | 0/18 | 0/18 |
| Dry skinSkin and subcutaneous tissue disorders | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| Nail dystrophySkin and subcutaneous tissue disorders | 0/18 | 1/9 | 0/9 | 0/18 | 0/18 |
| PurpuraSkin and subcutaneous tissue disorders | 0/18 | 0/9 | 1/9 | 0/18 | 0/18 |
| Age, Categorical(Participants) | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 9 | 8 | 18 | 17 | 69 |
| >=65 years | 1 | 0 | 1 | 0 | 1 | 3 |
| Age, Continuous(years) | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) | Total |
|---|---|---|---|---|---|---|
| Mean | 41.1 ± 11.70 | 36.3 ± 14.79 | 36.2 ± 17.29 | 36.3 ± 10.96 | 40.9 ± 11.48 | 38.6 ± 12.53 |
| Sex: Female, Male(Participants) | Placebo | Clazakizumab (150 IV/100 SC) | Clazakizumab (300 IV/100 SC) | Clazakizumab (400 SC/200 SC) | Clazakizumab (600 IV/200 SC) | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 5 | 7 | 10 | 9 | 45 |
| Male | 4 | 4 | 2 | 8 | 9 | 27 |
The record gives a start of Jun 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2021, 8 years after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab